Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Dianas terapéuticas en receptores de quimiocinas para seleccionar compuestos útiles para el tratamiento de patologías que intervienen en respuestas de quimiocinas

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20190506001
Publicado:
11/07/2019
Caducidad:
11/07/2020
Resumen:
Un centro español de investigación pública ha identificado una diana molecular en el dominio VI transmembrana de receptores de quimiocinas, específicamente en CXCR4, que se emplea para diseñar y detectar compuestos selectivos que modulan/antagonizan la función mediada por quimiocinas alterando la oligomerización del receptor, en contraste con las estrategias convencionales basadas en bloqueo de la unión de ligando. La modulación exógena de estas dianas terapéuticas permite bloquear específicamente algunos de los eventos desencadenados por el ligando a su receptor sin afectar a la unión del ligando. El centro de investigación busca socios en la industria farmacéutica para licenciar la patente.

Details

Tittle:
Therapeutic targets in chemokine receptors to select useful compounds for pathologies treatment that intervene in chemokine responses
Summary:
A Spanish public research institution has identified a molecular target in the transmembrane VI region of the chemokine receptors, specifically in CXCR4, that is used to design and detect selective compounds that modulate/antagonize chemokine-mediated function by altering receptor oligomerisation, in contrast to classical strategies based on ligand binding blockade.

Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent license agreement.
Description:
The residues responsible for chemokine-mediated receptor oligomerization are a therapeutic target that can be exogenously modulated in order to treat cancer metastasis, inflammatory and autoimmune diseases or HIV-1 infection.
The specific sequence within the amino acid sequence of the CXCR4 is directly involved in receptor oligomerization, being thus a promising therapeutic target to intervene in chemokine-mediated responses within cells.
All the technology required for the screening of small compounds acting on this target, both in vitro and in vivo, is available at the CNB lab.
Advantages and Innovations:
The invention falls within the fields of medicine and pharmacology, particularly within the field of therapeutic targets for the screening of compounds useful in the treatment of diseases or clinical conditions which symptoms or pathology are a consequence of the events triggered by chemokine signaling, such as inflammatory and autoimmune diseases, as well as cancer or HIV-1 infection.

The invention relates to the identification of molecular targets in chemokine receptors/chemokine complexes whose modulation is crucial to intervene in specific chemokine-mediated cell responses without altering others.

The exogenous modulation of these therapeutic targets would allow to specifically block some of the events triggered by the ligand to its receptor without affect ligand binding.

The invention has been tested in in vivo experiments using a murine model for neutrophils homing to the bone marrow.

The new target represents a completely new and effective approach to antagonize chemokine responses, opposed to the classical strategies based on ligand binding blockade that have always failed to obtain valuable drugs for clinical purposes.
Stage of Development:
Concept stage
IPs:
Patent(s) applied for but not yet granted

Partner sought

Type and Role of Partner Sought:
Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement.

Client

Type and Size of Client:
Industry >500
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06002002 Biología celular y molecular